The global biotech skincare market, the subset of skincare that uses biotech-derived ingredients, has been growing slowly and recently saw a spike of action. NewBeauty has highlighted “DNA-driven skin care”, meaning strategies that use polynucleotides (PN) or DNA fragments for skin repair, regeneration and texture improvement. Debut Biotech, a biotech ingredient company, is partnering with IMAGE Skincare to bring a new biotech active, produced via fermentation, into mainstream skincare. Debut, which makes lab-made ingredients for industries like skincare, beauty, nutrition and fragrances, has also raised US $20 million for AI-driven discovery of skin longevity ingredients.
The shift mirrors what is happening in healthcare. Personalized medicine is unfolding there as targeted cancer and disease therapies, and the same wave is now reaching skincare. With DNA testing, microbiome analysis and smart diagnostic devices, skincare is rapidly evolving into a data-driven, personalized system rather than a one-size-fits-all routine.
The numbers
The global biotech skincare market was valued at around USD 5.45 billion in 2024, and forecasts project it reaching approximately USD 8.25 billion by 2031, a CAGR (average growth per year) of about 5.8%. The broader personalized skincare products market is projected to grow from USD 26.2 billion in 2022 to about USD 48.65 billion by 2030, a CAGR of about 8.0%. The data is from Grand View Research.
Plotted together, the personalized skincare line climbs steadily from about USD 26 billion in 2022 to nearly USD 49 billion in 2030, while biotech skincare stays below USD 10 billion through 2031. Growth is moving slowly, but it may spike with the integration of AI and funding.
How DNA-driven skincare works
Polynucleotide (PN) therapy is a skincare and medical treatment that uses short strands of DNA to repair and rejuvenate skin, usually through microinjections. The DNA fragments repair skin cells, help boost cell regeneration, improve hydration and stimulate collagen. The result is improved texture and elasticity, with skin that looks smoother, firmer and healthier. From there the chain leads to personalized skincare solutions and to consumer products and serums.
PN therapy is one branch of DNA-driven skincare innovation. Other biotech skincare methods include microbiome balancing formulas, AI-formulated skin treatments, lab-grown ingredients, and peptide and protein engineering.
Outlook
Biotech skincare claims are compelling, but many formulations lag in high-quality long-term data or head-to-head comparisons. More intensive research and trials need to be conducted on larger and more diverse populations to confirm the results. Novel biotech products may also carry higher cost or complexity, so brands must balance price, margin and consumer uptake.
What to watch:
- Near term (1-2 years): more testing with higher quality data and compelling results, and some novel products hitting the shelves.
- Personalization will deepen: DNA, skin imaging and AI will drive potential “tailored” skincare kits or subscriptions.
- Biotech ingredients may migrate from premium to more mass tiers as cost and time decrease.
- New advancements may shift dermatology closer to regenerative therapy, not just symptom relief, furthering targeted treatments for conditions like rosacea, atopic dermatitis and acne (for example, peptides modulating inflammation or microbiome balance).
Personalized skincare treatment is still in the early stages, but it can exceed expectations with AI advancements and integration in the field.